We interviewed Dr. Aline Zimmer,Head of R&D, Advanced Cell Culture Technologies at Merckabout the importance of optimizing fed batch cell culture for successful biomanufacturing. Aline discussed how

Cell Culture Hero, Dr. Hillary Stires discusses her work researching better treatment options for triple positive breast cancer patients. She explains how the use of cell culture modeling helps drive her research.

In this podcast, we interviewed Dr. Rick Morris, Senior Vice President, R&D, Biotech, Pall Life Sciences, about integrating bioprocessing steps to improve efficiency, reduce cost and address current challenges in the industry.  Specifically,

In this podcast, we interviewed Mr. Dave Eansor President of the Protein Sciences Segment at Bio-Techne and Dr. Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne about new technologies that can be implemented to expedite cell and ge...

In this podcast, we interviewed Dr. Andreas Castan,Principal Scientist at GE Healthcare Life Sciencesabout the most efficient ways to optimize fed-batch cell culture production for CHO-based antibod

In this podcast, we interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the most efficient ways to optimize fed-batch cell culture production for CHO-based antibodies. This included a discussion of media vs. feed stra.

In this podcast, we interviewed Dr. Mats Lundgren, Ph.D. Customer Applications Director, Life Sciences, GE Healthcare, Swedenabout developing platform processes for viral vector manufacturing and Mat

In this podcast, we interviewed Dr. Mats Lundgren, Ph.D. Customer Applications Director, Life Sciences, GE Healthcare, Sweden about developing platform processes for viral vector manufacturing and Mats describes a recently developed platform process for .

This podcast is a recording from the panel discussion that I moderated at this years Cell and Gene Therapy Bioprocessing and Commercialization Conference. The discussion covers the latest in gene the

In this podcast, we conducted a panel discussion on key considerations for moving cell therapies from lab to commercial manufacturing, including the benefits of manufacturing in a closed system. We also discussed what were some of the key hurdles and pos.